This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (October 2009)

ISTA Pharmaceuticals, Inc.

Type	Public (NASDAQ: ISTA)
Founded	1992
Headquarters	Irvine, California
Key people	Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer
Industry	Pharmaceuticals
Products	Bepreve, Xibrom, Istalol, Vitrase
Website	http://www.istavision.com/

ISTA Pharmaceuticals, Inc, is a US based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.^[1]

Contents 1 Profile 2 Products 3 References 4 External links

[edit] Profile

ISTA currently markets Bepreve, Xibrom, Istalol, and Vitrase. ISTA also has several allergy and eye product candidates in various stages of development.

The company was founded in 1992 and is headquartered in Irvine, California.

[edit] Products

• Bepreve - (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis
• Xibrom - (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery
• Istalol - (timolol maleate ophthalmic solution) 0.5% for the treatment of glaucoma
• Vitrase - (hyaluronidase injection) Ovine, 200 USP Units/mL for use as a spreading agent.

[edit] References

[edit] External links

• ISTA homepage
• ISTA at Yahoo Finance

This United States corporation or company article is a stub. You can help Wikipedia by expanding it. v • d • e